Target family: Lipoxygenases (type: enzyme)
Target: 5-LOX

Ligand: 2-TEDC (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.050000190734863 pIC50
Reference (Journal): Novel caffeic acid derivatives: extremely potent inhibitors of 12-lipoxygenase.
Published in: J Med Chem

Ligand: 5-LOX activating protein (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: 5-LOX inhibitor 2m [PMID: 30199704] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.050000190734863 pIC50
Reference (Journal): Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
Published in: Eur J Med Chem

Ligand: BW B70C (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma.
Published in: Agents Actions Suppl

Ligand: CJ13610 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.150000095367432 pIC50
Reference (Journal): Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.
Published in: Br J Pharmacol

Ligand: Honokiol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.380000114440918 pIC50
Reference (Journal): Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation.
Published in: Bioorg Med Chem

Ligand: PF-04191834 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.639999866485596 pIC50
Reference (Journal): Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
Published in: J Pharmacol Exp Ther

Ligand: zileuton (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity: 6.400000095367432 pIC50
Reference (Journal): 5-lipoxygenase inhibitory activity of zileuton.
Published in: J Pharmacol Exp Ther

Ligand: zileuton (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity: 5.820000171661377 pIC50
Reference (Journal): Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
Published in: Eur J Med Chem

Ligand: zileuton (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Lead modification: amino acid appended indoles as highly effective 5-LOX inhibitors.
Published in: Bioorg Med Chem